S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Lacking counselors, US schools turn to the booming business of online therapy

Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

$24.29
+0.15 (+0.62%)
(As of 12/1/2023 ET)
Compare
Today's Range
$24.00
$24.43
50-Day Range
$23.37
$29.10
52-Week Range
$22.01
$33.71
Volume
4.35 million shs
Average Volume
1.77 million shs
Market Capitalization
$4.05 billion
P/E Ratio
19.59
Dividend Yield
N/A
Price Target
$32.29

Alkermes MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
32.9% Upside
$32.29 Price Target
Short Interest
Healthy
4.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
0.81mentions of Alkermes in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
59.26%
From $1.08 to $1.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.01 out of 5 stars

Medical Sector

20th out of 955 stocks

Pharmaceutical Preparations Industry

6th out of 447 stocks


ALKS stock logo

About Alkermes Stock (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Stock Price History

ALKS Stock News Headlines

Alkermes (NASDAQ:ALKS) Lifted to "Strong-Buy" at StockNews.com
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Alkermes Completes Separation of Oncology Business
Amgen (AMGN) Earnings Watch: Buy or Sell?
Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/25/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,280
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$32.29
High Stock Price Target
$35.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+32.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-158,270,000.00
Pretax Margin
13.68%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$0.25 per share
Book Value
$8.12 per share

Miscellaneous

Free Float
158,937,000
Market Cap
$4.05 billion
Optionable
Optionable
Beta
0.64

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














ALKS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price target for 2024?

7 analysts have issued 12 month price targets for Alkermes' shares. Their ALKS share price targets range from $28.00 to $35.00. On average, they predict the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2023?

Alkermes' stock was trading at $26.13 on January 1st, 2023. Since then, ALKS shares have decreased by 7.0% and is now trading at $24.29.
View the best growth stocks for 2023 here
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) announced its quarterly earnings results on Wednesday, October, 25th. The company reported $0.50 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.19. The company earned $380.94 million during the quarter, compared to analysts' expectations of $366.18 million. Alkermes had a trailing twelve-month return on equity of 11.41% and a net margin of 13.50%.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY23 earnings guidance on Wednesday, November, 15th. The company provided earnings per share (EPS) guidance of $1.57-$1.75 for the period, compared to the consensus EPS estimate of $1.58.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.04%), Hardman Johnston Global Advisors LLC (3.37%), Primecap Management Co. CA (2.33%), Bank of New York Mellon Corp (1.66%), Charles Schwab Investment Management Inc. (1.30%) and Morgan Stanley (1.21%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
This page (NASDAQ:ALKS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -